Black patients with chronic hepatitis C have a lower sustained viral response rate than non-Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin

Journal of Viral Hepatitis

Volumn 13, Issue 4, 2006, Pages 242-249

  Brau N ^a,c   Bini, E J ^b   Currie, S ^b,d   Shen, H ^b,d   Schmidt, W N ^b   King, P D ^b   Ho, S B ^b   Cheung, R C ^b   Hu, K Q ^b   Anand, B S ^b   Simon, F R ^b   Aytaman, A ^b   Johnson, D P ^b   Awad, J A ^b   Ahmad, J ^b   Mendenhall, C L ^b   Pedrosa, M C ^b   Moseley, R H ^b   Hagedorn, C H ^b   Waters, B ^b   Chang, K M ^b   Morgan, T R ^b   Rossi, S J ^b   Jeffers, L J ^b   Wright, T L ^b,d   more..

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b Mount Sinai School of Medicine ^*

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Community based practice; Dose reduction; Hepatitis C; Racial differences; Therapy

Indexed keywords

ALPHA2B INTERFERON; ANTIVIRUS AGENT; HEMOGLOBIN; RIBAVIRIN;

ADULT; ALOPECIA; AMERICAN INDIAN; ANEMIA; ARTICLE; ASIAN; CAUCASIAN; CLINICAL TRIAL; COMMUNITY ASSESSMENT; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DEPRESSION; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FLU LIKE SYNDROME; FREQUENCY ANALYSIS; GENETIC VARIABILITY; GENOTYPE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK POPULATION; HUMAN; INFECTION RISK; INJECTION SITE REACTION; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MYALGIA; NAUSEA; NEGRO; NEUTROPHIL COUNT; PNEUMONIA; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RACE DIFFERENCE; RISK ASSESSMENT; TREATMENT RESPONSE; VOMITING;

EID: 33645065351     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2005.00682.x     Document Type: Article

References (20)

1. Hadziyannis SJ Sette H Jr. Morgan TR et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose Ann Intern Med 2004 140 5 346 355
2. Manns MP McHutchison JG Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 2001 358 9286 958 965
3. Howell C Jeffers L Hoofnagle JH Hepatitis C in African Americans: summary of a workshop Gastroenterology 2000 119 5 1385 1396
4. McHutchison JG Poynard T Pianko S et al. The impact of interferon plus ribavirin on response to therapy in Black patients with chronic hepatitis C Gastroenterology 2000 119 5 1317 1323
5. Bini EJ Bräu N Currie S et al. Prospective Multicenter Study of eligibility for antiviral therapy among 4,084 US veterans with chronic hepatitis C virus infection Am J Gastroenterol 2005 100 (8) 1772 1779
6. Poynard T Marcellin P Lee SS et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) Lancet 1998 352 9138 1426 1432
7. McHutchison JG Gordon SC Schiff ER et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group [see comments] N Engl J Med 1998 339 21 1485 1492
8. Schering Corporation Rebetron® Product Information Kenilworth, NJ Schering Corporation 2003
9. Ludwig J Histopathological diagnosis and terminology of chronic hepatitis J Hepatol 1995 23 Suppl 1 49 53
10. Alter MJ Kruszon-Moran D Nainan OV et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994 N Engl J Med 1999 341 8 556 562
11. Shiffman ML Di Bisceglie AM Lindsay KL et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment Gastroenterology 2004 126 4 1015 1023
12. Reddy KR Hoofnagle JH Tong MJ et al. Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group Hepatology 1999 30 3 787 793
13. Kinzie JL Naylor PH Nathani MG et al. African Americans with genotype 1 treated with interferon for chronic hepatitis C have a lower end of treatment response than Caucasians J Viral Hepat 2001 8 4 264 269
14. Morelli J Kim CY Willner IR U.S. veterans' experience with rebetron in a nonstudy environment: success or failure Am J Gastroenterol 2002 97 9 2379 2382
15. Layden-Almer JE Ribeiro RM Wiley T Perelson AS Layden TJ Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin Hepatology 2003 37 6 1343 1350
16. Theodore D Shiffman ML Sterling RK et al. Intensive interferon therapy does not increase virological response rates in African Americans with chronic hepatitis C Dig Dis Sci 2003 48 1 140 145
17. Jeffers LJ Cassidy W Howell CD Hu S Reddy KR Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1 Hepatology 2004 39 6 1702 1708
18. Muir AJ Bornstein JD Killenberg PG Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites N Engl J Med 2004 350 22 2265 2271
19. Reed WW Diehl LF Leukopenia, neutropenia, and reduced hemoglobin levels in healthy American blacks Arch Intern Med 1991 151 3 501 505
20. Grattagliano I Russmann S Palmieri VO et al. Low membrane protein sulfhydrils but not G6PD deficiency predict ribavirin-induced hemolysis in hepatitis C Hepatology 2004 39 5 1248 1255